• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Replimune Group Inc.

    2/14/25 9:00:03 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $REPL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    REPLIMUNE GROUP, INC.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    76029N106

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    76029N106


    1Names of Reporting Persons

    Forbion Capital Fund III Cooperatief U.A.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,219,340.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,219,340.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,219,340.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Includes 248,672 shares of Common Stock issuable upon exercise of warrants to purchase shares of Common Stock. The percent of class is calculated based upon (i) 68,417,444 outstanding shares of Common Stock of the Issuer, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 12, 2024, plus (ii) 248,672 shares of Common Stock underlying warrants held by the Reporting Persons.


    SCHEDULE 13G

    CUSIP No.
    76029N106


    1Names of Reporting Persons

    Forbion III Management B.V.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,219,340.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,219,340.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,219,340.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Includes 248,672 shares of Common Stock issuable upon exercise of warrants to purchase shares of Common Stock. The percent of class is calculated based upon (i) 68,417,444 outstanding shares of Common Stock of the Issuer, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 12, 2024, plus (ii) 248,672 shares of Common Stock underlying warrants held by the Reporting Persons.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    REPLIMUNE GROUP, INC.
    (b)Address of issuer's principal executive offices:

    500 Unicorn Park Drive, Suite 303, Woburn, MA 01801
    Item 2. 
    (a)Name of person filing:

    This Statement is being filed by Forbion Capital Fund III Cooperatief U.A. ("Forbion III COOP"), and Forbion III Management B.V. ("Forbion III"), the director of Forbion III COOP. Forbion III COOP and Forbion III are sometimes referred to collectively herein as the "Reporting Persons".
    (b)Address or principal business office or, if none, residence:

    The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.
    (c)Citizenship:

    Each of the Reporting Persons is organized under the laws of the Netherlands.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    76029N106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Forbion III COOP is the beneficial owner of 4,219,340 shares of Common Stock, consisting of (i) 3,970,668 shares of Common Stock and (ii) 248,672 shares of Common Stock issuable upon exercise of warrants beneficially owned by the Reporting Persons. Forbion III, the director of Forbion III COOP, has voting and investment power over the shares held by Forbion III COOP.
    (b)Percent of class:

    6.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    4,219,340

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    4,219,340

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    The Reporting Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a "group" for purposes of Rule 13d-5 or for any other purpose.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Forbion Capital Fund III Cooperatief U.A.
     
    Signature:/s/ G.J Mulder and /s/ V. van Houten
    Name/Title:Directors of its Director
    Date:02/14/2025
     
    Forbion III Management B.V.
     
    Signature:/s/ G.J Mulder and /s/ V. van Houten
    Name/Title:Directors
    Date:02/14/2025
    Get the next $REPL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REPL

    DatePrice TargetRatingAnalyst
    11/3/2025$11.00Underperform → Market Perform
    BMO Capital Markets
    10/27/2025$12.00Neutral → Buy
    H.C. Wainwright
    10/20/2025$13.00Neutral → Overweight
    Piper Sandler
    10/20/2025Underweight → Neutral
    Analyst
    10/20/2025$13.00Market Perform → Outperform
    Leerink Partners
    10/20/2025$18.00Neutral → Outperform
    Wedbush
    9/19/2025Neutral → Underweight
    Analyst
    7/30/2025Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $REPL
    SEC Filings

    View All

    SEC Form 10-Q filed by Replimune Group Inc.

    10-Q - Replimune Group, Inc. (0001737953) (Filer)

    2/3/26 8:12:07 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Replimune Group, Inc. (0001737953) (Filer)

    2/3/26 8:05:37 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Replimune Group, Inc. (0001737953) (Filer)

    1/12/26 8:00:43 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $REPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Patel Sushil was granted 200,000 shares, increasing direct ownership by 60% to 533,576 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    12/19/25 5:14:48 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Xynos Konstantinos was granted 60,000 shares, increasing direct ownership by 43% to 199,685 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    12/19/25 5:13:28 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Hill Emily Luisa was granted 60,000 shares, increasing direct ownership by 45% to 194,368 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    12/19/25 5:12:10 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $REPL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

    WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a business update. The Company's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in anti-PD-1 failed melanoma was accepted by the FDA in October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of April 10, 2026. Commercial readiness activities are well underway to support a potential launch, if approved. The Company has amended its existing lo

    2/3/26 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

    WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About ReplimuneReplimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the developmen

    12/18/25 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

    WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that biomarker data and updated clinical data from the IGNYTE clinical trial of RP1 plus nivolumab was presented as a late-breaking abstract during an oral session at the 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) in National Harbor, Maryland. Two additional posters on RP1 are also being presented. "These data are important because they demonstrate that RP1 plus nivolumab can potentially reprogram the tumor microenvironment and reverse mechanisms of res

    11/7/25 4:45:00 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $REPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Replimune upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Replimune from Underperform to Market Perform and set a new price target of $11.00

    11/3/25 9:08:28 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Replimune from Neutral to Buy and set a new price target of $12.00

    10/27/25 8:31:26 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Replimune from Neutral to Overweight and set a new price target of $13.00

    10/20/25 4:00:35 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $REPL
    Leadership Updates

    Live Leadership Updates

    View All

    Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

    Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

    5/8/25 5:00:00 AM ET
    $COYA
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

    Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip

    3/26/24 7:30:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tessellate BIO Emerges from Stealth

    The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s

    10/17/23 3:00:00 AM ET
    $NAMS
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $REPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 4:20:10 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 1:22:38 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 8:35:56 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $REPL
    Financials

    Live finance-specific insights

    View All

    Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

    WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the

    5/16/25 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

    Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat

    6/6/24 7:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

    RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s

    12/5/23 7:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care